Arcadia Biosciences Statistics
Share Statistics
Arcadia Biosciences has 1.36M shares outstanding. The number of shares has increased by 22.93% in one year.
| Shares Outstanding | 1.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.36M |
| Failed to Deliver (FTD) Shares | 18.16K |
| FTD / Avg. Volume | 1.47% |
Short Selling Information
The latest short interest is 116.14K, so 8.51% of the outstanding shares have been sold short.
| Short Interest | 116.14K |
| Short % of Shares Out | 8.51% |
| Short % of Float | 8.57% |
| Short Ratio (days to cover) | 0.03 |
Valuation Ratios
The PE ratio is -0.28 and the forward PE ratio is -3.23.
| PE Ratio | -0.28 |
| Forward PE | -3.23 |
| PS Ratio | 0.73 |
| Forward PS | 0.8 |
| PB Ratio | 0.3 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | n/a |
Enterprise Valuation
Arcadia Biosciences Inc. has an Enterprise Value (EV) of -1.64M.
| EV / Earnings | 0.12 |
| EV / Sales | -0.31 |
| EV / EBITDA | 0.12 |
| EV / EBIT | 0.12 |
| EV / FCF | 0.11 |
Financial Position
The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.
| Current Ratio | 4.17 |
| Quick Ratio | 3.63 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on capital (ROIC) is -101.72%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.71% |
| Return on Capital (ROIC) | -101.72% |
| Revenue Per Employee | 253.81K |
| Profits Per Employee | -665.76K |
| Employee Count | 21 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | 8.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 91.41% in the last 52 weeks. The beta is 1.27, so Arcadia Biosciences 's price volatility has been higher than the market average.
| Beta | 1.27 |
| 52-Week Price Change | 91.41% |
| 50-Day Moving Average | 4.66 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 43.56 |
| Average Volume (20 Days) | 1.23M |
Income Statement
In the last 12 months, Arcadia Biosciences had revenue of 5.33M and earned -13.98M in profits. Earnings per share was -11.3.
| Revenue | 5.33M |
| Gross Profit | 2.03M |
| Operating Income | -13.94M |
| Net Income | -13.98M |
| EBITDA | -13.58M |
| EBIT | -13.94M |
| Earnings Per Share (EPS) | -11.3 |
Balance Sheet
The company has 6.52M in cash and 1.01M in debt, giving a net cash position of 5.51M.
| Cash & Cash Equivalents | 6.52M |
| Total Debt | 1.01M |
| Net Cash | 5.51M |
| Retained Earnings | -271.84M |
| Total Assets | 15.24M |
| Working Capital | 8.38M |
Cash Flow
In the last 12 months, operating cash flow was -15.29M and capital expenditures -5.00K, giving a free cash flow of -15.30M.
| Operating Cash Flow | -15.29M |
| Capital Expenditures | -5.00K |
| Free Cash Flow | -15.30M |
| FCF Per Share | -12.37 |
Margins
Gross margin is 38.09%, with operating and profit margins of -261.5% and -262.31%.
| Gross Margin | 38.09% |
| Operating Margin | -261.5% |
| Pretax Margin | -246.85% |
| Profit Margin | -262.31% |
| EBITDA Margin | -254.75% |
| EBIT Margin | -261.5% |
| FCF Margin | -287.04% |
Dividends & Yields
RKDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -230.61% |
| FCF Yield | -228.75% |
Analyst Forecast
The average price target for RKDA is $6, which is 22.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 22.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 1, 2023. It was a backward split with a ratio of 1:40.
| Last Split Date | Mar 1, 2023 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -25.43 |
| Piotroski F-Score | 2 |